RXDX Ignyta, Inc.

8.95
+1  (6%)
Previous Close 8.45
Open 8.60
Price To book 3.71
Market Cap 373.22M
Shares 41,700,000
Volume 1,136,779
Short Ratio 1.70
Av. Daily Volume 323,626

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b data update 2H 2017.
RXDX-105
Solid tumors - cancer
Ongoing.
Taladegib
Ovarian cancer
Phase 2 trial initiated September 2015. Comprehensive update due April 27, 2017.
STARTRK-2 entrectinib
Solid tumors - cancer

Latest News

  1. Ignyta to Host Conference Call and Webcast Update on Entrectinib Program and STARTRK-2 on April 27, 2017
  2. Ignyta Announces New Data Highlighting Broad Potential of Both RXDX-106 and Entrectinib at the 2017 AACR Annual Meeting
  3. Ignyta Announces Peer-Reviewed Publication of Activity of a TRK Inhibitor in a Primary Brain Tumor: Successful Treatment of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published in Precision Oncology
  4. Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting
  5. Ignyta Announces Exploration of Strategic Options for Taladegib, Enabled by Amendment of Taladegib License Agreement with Lilly
  6. Ignyta Announces Full Year 2016 Company Highlights and Financial Results
  7. Angsana's RNA-based fusions cancer panel selected for Ignyta's STARTRK2 clinical trial in Asia-Pacific
  8. Ignyta's Updated Phase 1 Data on Safety, Anti-Tumor Activity and CNS Activity of Entrectinib in Cancers with TRK, ROS1 or ALK Fusions Published in Cancer Discovery
  9. Ignyta to Present at the LEERINK Partners 6th Annual Global Healthcare Conference
  10. Ignyta to Present at 35th Annual J.P. Morgan Healthcare Conference
  11. Loxo Oncology Aims for Genetic Mutation Cancer Drug Approval in 2018
  12. Ignyta, Inc. :RXDX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016
  13. Is Ignyta Inc (RXDX) A Good Stock To Buy?
  14. Ignyta Appoints Steven L. Hoerter, Chief Commercial Officer of Agios Pharmaceuticals, Inc., to Board of Directors
  15. Late-Breaking Oral Plenary Presentation of a Novel Entrectinib Combination Regimen at the 2016 EORTC-NCI-AACR Annual Meeting
  16. Ignyta Announces Compelling Phase 1/1b Clinical Data on RXDX-105, Its VEGFR-Sparing RET Inhibitor, at the 2016 EORTC-NCI-AACR Annual Meeting
  17. Ignyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting
  18. Ignyta to Present at 28th Annual Piper Jaffray Healthcare Conference
  19. Ignyta Announces EAP Designation and CE Marking for its Trailblaze Pharos™ Clinical Trial Assay
  20. Ignyta Announces Six Upcoming Presentations at the 2016 EORTC-NCI-AACR Annual Meeting